




Name	Dong-Yeop Shin	
Current Position	Associate Professor	
Country	South Korea	
Major Field	Leukemia and transplant	

Educational Background

2012 ~ 2015 Doctor of Philosophy (Molecular Oncology), Graduate School, Seoul National University, Seoul, Korea
(Thesis: The role of histone deacetylase inhibitor romidepsin in EBV-positive diffuse large B-cell lymphoma)

2009 ~ 2011 Master of Science, Graduate School, Seoul National University, Seoul, Korea

2002 ~ 2006 College of Medicine, Seoul National University, Seoul, Korea

Professional Experience

2020 - present Associate Professor, Division of Hematology & Medical Oncology, Department of Internal Medicine, Seoul National University Hospital.

2019 - 2020 Visiting Scholar, Hal Broxmeyer lab, Department of Microbiology and Immunology, Indiana University School of Medicine, IN, U.S.

2016 ~ 2020 Assistant Professor, Division of Hematology & Medical Oncology, Department of Internal Medicine, Seoul National University Hospital.

2012 ~ 2016 Staff Physician, Division of Hematology & Medical Oncology, Department of Internal Medicine, Korea Cancer Center Hospital

2011 ~ 2012 Clinical Fellow, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital

Other Experience and Professional Memberships

Director of Scientific Committee (Jul 2022~ Jun 2024), Korean Society of Hematology (KSH)

Member (2012~ present), Scientific Committee Vice-chair (2020~2022), Health Insurance Committee (2020~ present), Korean Society of Hematology (KSH)

Scientific Program Committee Vice-chair, (2021~2022), International Conference for KSH.

Member (2016 ~ present), Secretary (2020~ present), Korean Acute Myeloid Leukemia/Myelodysplastic Syndrome Working Party (AML/MDS WP)

Member (2010 ~ present), Secretary of Scientific Committee (2016~2017), Cord Blood Transplant Committee, Korean Society of Blood and Marrow Transplant (KSBMT)

Main Scientific Publications

Hwang YJ, **Shin DY**, Kim MJ, Jang H, Kim S, Yang H, Jang WI, Park S, Shim S, Lee SB. StemRegenin-1 Mitigates Radiation-Mediated Hematopoietic Injury by Modulating Radioresponse of Hematopoietic Stem/Progenitor Cells. *Biomedicines* 2023 ;11(3): 824 (co-1st author)



Kim D, **Shin DY**, Liu J, Jeong NR, Koh Y, Hong J, Huang X, Broxmeyer HE, Yoon SS. Expansion of Human Megakaryocyte-Lineage Progeny via Aryl Hydrocarbon Receptor Antagonism with CH223191. *Stem Cell Rev Rep.* 2022 Dec ; 18(8): 2892-2994 (*Corresponding author*)

Shin DY, Huang X, Gil CH, Aljouji A, Ropa J, Broxmeyer HE. Physioxia enhances T-cell development ex vivo from human hematopoietic stem and progenitor cells. *Stem Cells* 2020 Nov;38(11): 1454-1466.

Shin DY, Park JK, Kim SM, Im K, Kim JA, Kim SY, Hwang SM, Yoon SS, Lee DS. The role of ASXL1 mutation in idiopathic cytopenia of undetermined significance. *Leukemia and Lymphoma* 2019 Mar; 60(3): 756-763

Shin DY, Park JK, Li CC, Park HS, Moon SY, Kim SM, Im K, Chang YH, Yoon SS, Lee DS. Replicative senescence of hematopoietic cells in patients with idiopathic cytopenia of undetermined significance. *Leuk Res.* 2019 Apr;79:22-26

Shin DY, Lim KM, Park HS, Kwon S, Yoon SS, Lee DS. The importance of critically short telomere in myelodysplastic syndrome. *Biomark Res* 2022 ;10(1):79

Park S, **Shin DY**, Park JS, Moon SY, Yoon SS, Lee DS. Increased apoptotic activity in low-risk myelodysplastic syndrome. *J Clin Med* 2022 Aug 7: 11: 4604 (*Corresponding author*)

Kim S, **Shin DY**, Kim D, Oh S, Hong J, Kim I, Kim E. Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes Cells. 2022 Dec 10; 10(12): 3494 (*Co-1st author*)

Oh YJ, **Shin DY**, Hwang SM, Kim SM, Im K, Park HS, Kim JA, Song YW, Marquez A, Martin J, Lee DS, Park JK. Mutation of Ten-Eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome. *Korean J Intern Med* 2020 Mar; 35(2):457-464 (*Co-1st author*)

Shin DY. Human acute myeloid leukemia stem cells: evolution of concept. *Blood Res* 2022 Apr 30; 57(S1): 67-74 (*sole author*)

Kim HK, Son SY, Oh JS, Song YN, Byun JM, Koh Y, Hong J, Yoon SS, Lee CH, **Shin DY**, Lee MR. Metabolic profiling during acute myeloid leukemia progression using paired clinical bone marrow serum samples. *Metabolites.* 2021 Aug 31; 11(9): 586 (*Co-corresponding author*)

Han H, Byun JM, **Shin DY**, Toon SS, Koh Y, Hong J, Kim I, Yoo H, Yun H, Kim MJ, Cho SI, Seong MW, Park SS. Leukemic stem cell phenotype is associated with mutational profile in acute myeloid leukemia. *Korean J Intern Med.* 2021 Mar;36(2): 401-412 (*Corresponding author*)

Han H, **Shin DY**, Kim D, Kim H, Lee C, Koh Y, Hong J, Yoon SS. Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD+ acute myeloid leukemia. *Leuk Lymphoma* 2020 May 6;1-11 (*Co-1st author*)

Shin DY, Lee JH, Park S, Lee JO, Moon JH, Ahn JS, Choi Y, Song IC, Shin HJ, Lee WD, Lee HS, Yoon SS. Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignancies. *Bone Marrow Transplant.* 2018. Feb; 53(2): 207-212

Choi M, **Shin DY**, Lee JY, Kim I, Yoon SS, Bang SM. Differential impact of anti-thymocyte globulin dosing by disease risk index in alternative donor peripheral blood stem cell transplantation in patients with acute leukemia or myelodysplastic syndrome after reduced intensity conditioning. *Blood Res.* 2019 Dec; 54(4): 2900-295 (*Corresponding author*)
